• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性外周神经鞘膜瘤的临床及分子预后预测指标

Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor.

作者信息

Fan Q, Yang J, Wang G

机构信息

Department of Intensive Care, Henan Provincial People's Hospital, Zhengzhou, 450003, China.

出版信息

Clin Transl Oncol. 2014 Feb;16(2):191-9. doi: 10.1007/s12094-013-1061-x. Epub 2013 Jun 8.

DOI:10.1007/s12094-013-1061-x
PMID:23749326
Abstract

OBJECTIVE

Malignant peripheral nerve sheath tumors (MPNST) are relatively rare sarcomas and poorly understood. We sought to find clinicopathological and molecular predictors of survival for Chinese MPNST patients.

METHODS

Clinical information from 146 MPNST patients treated in the Tianjin Medical University Cancer Institute and Hospital was collected and 56 cases of formalin-fixed and paraffin-embedded tissues were available for immunohistochemical examination of expression of hepatocyte growth factor receptor (c-MET), E3 ubiquitin-protein ligase Mdm2 (MDM2), and TP53.

RESULTS

The 5-year tumor-free survival rate was 24 % and the median tumor-free survival time was 25.64 months. The 5-year overall survival rate was 57 % and the median overall survival time was 132.57 months. The expression patterns of c-MET, TP53, and MDM2 were heterogeneous with total positivity rates of 82.1 % (46/56), 55.4 % (31/56), and 73.2 % (41/56), respectively. The univariate analysis not only showed that tumor size, Neurofibromin 1 (NF1) status, the American Joint Committee on Cancer (AJCC) stage, surgery, MDM2 expression, and TP53 expression had significant correlation with the tumor-free survival, but also demonstrated that radiotherapy, chemotherapy, tumor size, and NF1 status had significant correlation with the overall survival. Even though multivariate analysis found no independent prognostic predictor of MPNST, tumor size and NF1 status had significant correlation with the tumor-free survival and overall survival of MPNST patients.

CONCLUSIONS

With this, the largest documented Chinese cohort, our data supply powerful Chinese evidence of the prognostic role of tumor size and NF1 status in MPNST.

摘要

目的

恶性外周神经鞘膜瘤(MPNST)是相对罕见的肉瘤,人们对其了解较少。我们试图找出中国MPNST患者生存的临床病理和分子预测指标。

方法

收集了天津医科大学肿瘤医院治疗的146例MPNST患者的临床信息,56例福尔马林固定石蜡包埋组织可用于免疫组化检测肝细胞生长因子受体(c-MET)、E3泛素蛋白连接酶Mdm2(MDM2)和TP53的表达。

结果

5年无瘤生存率为24%,中位无瘤生存时间为25.64个月。5年总生存率为57%,中位总生存时间为132.57个月。c-MET、TP53和MDM2的表达模式具有异质性,总阳性率分别为82.1%(46/56)、55.4%(31/56)和73.2%(41/56)。单因素分析不仅显示肿瘤大小、神经纤维瘤蛋白1(NF1)状态、美国癌症联合委员会(AJCC)分期、手术、MDM2表达和TP53表达与无瘤生存显著相关,还表明放疗、化疗、肿瘤大小和NF1状态与总生存显著相关。尽管多因素分析未发现MPNST的独立预后预测指标,但肿瘤大小和NF1状态与MPNST患者的无瘤生存和总生存显著相关。

结论

通过这个最大的中国文献报道队列,我们的数据提供了有力的中国证据,证明肿瘤大小和NF1状态在MPNST中的预后作用。

相似文献

1
Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor.恶性外周神经鞘膜瘤的临床及分子预后预测指标
Clin Transl Oncol. 2014 Feb;16(2):191-9. doi: 10.1007/s12094-013-1061-x. Epub 2013 Jun 8.
2
Malignant peripheral nerve sheath tumours: high Ki67 labelling index is the significant prognostic indicator.恶性周围神经鞘膜瘤:高Ki67标记指数是重要的预后指标。
Histopathology. 2001 Aug;39(2):187-97. doi: 10.1046/j.1365-2559.2001.01176.x.
3
Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor.免疫组织化学评估 cyclin D1 和 p53 与儿童恶性外周神经鞘瘤的生存相关。
Cancer Biomark. 2019;24(3):351-361. doi: 10.3233/CBM-181572.
4
[Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: a retrospective study of 140 cases].恶性周围神经鞘膜瘤的临床病理特征及预后:140例回顾性研究
Zhonghua Zhong Liu Za Zhi. 2017 Jun 23;39(6):439-444. doi: 10.3760/cma.j.issn.0253-3766.2017.06.008.
5
Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.预测恶性外周神经鞘瘤预后的临床、病理和分子变量。
Ann Surg. 2009 Jun;249(6):1014-22. doi: 10.1097/SLA.0b013e3181a77e9a.
6
Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors.透明质酸表达作为恶性外周神经鞘膜瘤患者的重要预后因素
Clin Exp Metastasis. 2014 Aug;31(6):715-25. doi: 10.1007/s10585-014-9662-5. Epub 2014 Jun 24.
7
Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.临床基因组分析鉴定出1型神经纤维瘤病相关恶性外周神经鞘膜瘤患者中的酪氨酸激酶2(TYK2)突变和过表达。
Cancer. 2017 Apr 1;123(7):1194-1201. doi: 10.1002/cncr.30455. Epub 2016 Nov 22.
8
Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor.成纤维细胞生长因子受体家族成员在恶性外周神经鞘瘤中的预后作用
Oncotarget. 2016 Apr 19;7(16):22234-44. doi: 10.18632/oncotarget.8067.
9
Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.NF1 相关和散发性恶性外周神经鞘瘤中 AKT/mTOR 和 MAPK 通路的预后意义及 mTOR 抑制剂的抗肿瘤作用。
Clin Cancer Res. 2013 Jan 15;19(2):450-61. doi: 10.1158/1078-0432.CCR-12-1067. Epub 2012 Dec 3.
10
Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.散发型、神经纤维瘤病 1 型相关和放射相关恶性外周神经鞘瘤的复发和生存模式。
J Neurosurg. 2017 Jan;126(1):319-329. doi: 10.3171/2015.12.JNS152443. Epub 2016 Apr 1.

引用本文的文献

1
[Analysis of clinical features, treatment methods, and prognostic influence factors in patients with malignant peripheral nerve sheath tumor].[恶性周围神经鞘膜瘤患者的临床特征、治疗方法及预后影响因素分析]
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024 Oct 15;38(10):1193-1201. doi: 10.7507/1002-1892.202406040.
2
Local recurrence in malignant peripheral nerve sheath tumours: multicentre cohort study.恶性外周神经鞘瘤的局部复发:多中心队列研究。
BJS Open. 2024 Mar 1;8(2). doi: 10.1093/bjsopen/zrae024.
3
Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis.

本文引用的文献

1
Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.恶性外周神经鞘瘤的基因组和分子特征表明 IGF1R 通路是治疗的主要靶点。
Clin Cancer Res. 2011 Dec 15;17(24):7563-73. doi: 10.1158/1078-0432.CCR-11-1707. Epub 2011 Oct 31.
2
Therapeutics for childhood neurofibromatosis type 1 and type 2.儿童神经纤维瘤病 1 型和 2 型的治疗方法。
Curr Treat Options Neurol. 2011 Dec;13(6):529-43. doi: 10.1007/s11940-011-0142-9.
3
Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma.
神经纤维瘤病 I 型(NF1)伴发与不伴发的恶性外周神经鞘瘤(MPNST)的生存结局:一项荟萃分析。
World J Surg Oncol. 2024 Jan 9;22(1):14. doi: 10.1186/s12957-023-03296-z.
4
The role of radiotherapy in the management of malignant peripheral nerve sheath tumors: a single-center retrospective cohort study.放疗在恶性外周神经鞘瘤治疗中的作用:单中心回顾性队列研究。
J Cancer Res Clin Oncol. 2023 Dec;149(20):17739-17747. doi: 10.1007/s00432-023-05449-9. Epub 2023 Nov 4.
5
Clinical Outcomes and Prognostic Factors for Patients with Malignant Peripheral Nerve Sheath Tumour.恶性周围神经鞘膜瘤患者的临床结局及预后因素
Sarcoma. 2021 Nov 24;2021:8335290. doi: 10.1155/2021/8335290. eCollection 2021.
6
Parotid Neurogenic Tumors: MPNST Sarcoma to Schwannoma-Review of Literature and Guidelines in Management.腮腺神经源性肿瘤:从恶性周围神经鞘膜瘤到神经鞘瘤——文献综述与管理指南
J Maxillofac Oral Surg. 2021 Sep;20(3):356-363. doi: 10.1007/s12663-021-01523-2. Epub 2021 Mar 23.
7
Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival.恶性外周神经鞘膜瘤的组织病理学发现可预测放疗反应和总生存期。
Neurooncol Adv. 2020 Oct 1;2(1):vdaa131. doi: 10.1093/noajnl/vdaa131. eCollection 2020 Jan-Dec.
8
Prognostic Significance of Immunohistochemical Markers and Genetic Alterations in Malignant Peripheral Nerve Sheath Tumors: A Systematic Review.免疫组织化学标志物和基因改变在恶性外周神经鞘膜瘤中的预后意义:一项系统评价
Front Oncol. 2020 Dec 22;10:594069. doi: 10.3389/fonc.2020.594069. eCollection 2020.
9
Prognosis and risk factors for malignant peripheral nerve sheath tumor: a systematic review and meta-analysis.恶性外周神经鞘膜瘤的预后及危险因素:一项系统评价与荟萃分析
World J Surg Oncol. 2020 Sep 30;18(1):257. doi: 10.1186/s12957-020-02036-x.
10
Arm malignant peripheral nerve sheath tumour: a rare clinical presentation.手臂恶性周围神经鞘膜瘤:一种罕见的临床表现。
BMJ Case Rep. 2019 Aug 15;12(8):e229852. doi: 10.1136/bcr-2019-229852.
人类骨肉瘤中血管内皮生长因子(VEGF)通路基因(包括 VEGFA)的遗传扩增。
Cancer. 2011 Nov 1;117(21):4925-38. doi: 10.1002/cncr.26116. Epub 2011 Apr 14.
4
Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.预测恶性外周神经鞘瘤预后的临床、病理和分子变量。
Ann Surg. 2009 Jun;249(6):1014-22. doi: 10.1097/SLA.0b013e3181a77e9a.
5
Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors.鉴定p53作为恶性外周神经鞘膜瘤患者生存的强预测指标。
Neuro Oncol. 2009 Oct;11(5):514-28. doi: 10.1215/15228517-2008-127. Epub 2009 Jan 30.
6
Malignant peripheral nerve sheath tumors.恶性外周神经鞘瘤
Neurosurg Clin N Am. 2008 Oct;19(4):533-43, v. doi: 10.1016/j.nec.2008.07.004.
7
Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.人恶性外周神经鞘膜瘤高级别区域中表皮生长因子受体(EGFR)频繁呈阳性及过表达
Sarcoma. 2008;2008:849156. doi: 10.1155/2008/849156.
8
Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations.恶性周围神经鞘膜瘤:分子发病机制及当前治疗考量
J Surg Oncol. 2008 Mar 15;97(4):340-9. doi: 10.1002/jso.20971.
9
High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization.使用基于靶向微阵列的比较基因组杂交技术对恶性外周神经鞘瘤进行高分辨率DNA拷贝数分析。
Clin Cancer Res. 2008 Feb 15;14(4):1015-24. doi: 10.1158/1078-0432.CCR-07-1305.
10
Unlocking the Mdm2-p53 loop: ubiquitin is the key.解开Mdm2-p53循环:泛素是关键。
Cell Cycle. 2008 Feb 1;7(3):287-92. doi: 10.4161/cc.7.3.5358. Epub 2007 Nov 25.